DE3581830D1 - Kontrastmittel zur bilderzeugung mittels magnetischer kernresonanz. - Google Patents

Kontrastmittel zur bilderzeugung mittels magnetischer kernresonanz.

Info

Publication number
DE3581830D1
DE3581830D1 DE8585302995T DE3581830T DE3581830D1 DE 3581830 D1 DE3581830 D1 DE 3581830D1 DE 8585302995 T DE8585302995 T DE 8585302995T DE 3581830 T DE3581830 T DE 3581830T DE 3581830 D1 DE3581830 D1 DE 3581830D1
Authority
DE
Germany
Prior art keywords
vesicles
magnetic core
image generation
contrast agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585302995T
Other languages
English (en)
Inventor
Ronald Carl Gamble
Paul Gardner Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexstar Pharmaceuticals Inc
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vestar Inc filed Critical Vestar Inc
Application granted granted Critical
Publication of DE3581830D1 publication Critical patent/DE3581830D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
DE8585302995T 1984-04-27 1985-04-26 Kontrastmittel zur bilderzeugung mittels magnetischer kernresonanz. Expired - Lifetime DE3581830D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60472184A 1984-04-27 1984-04-27
US06/720,954 US4728575A (en) 1984-04-27 1985-04-10 Contrast agents for NMR imaging

Publications (1)

Publication Number Publication Date
DE3581830D1 true DE3581830D1 (de) 1991-04-04

Family

ID=27084736

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585302995T Expired - Lifetime DE3581830D1 (de) 1984-04-27 1985-04-26 Kontrastmittel zur bilderzeugung mittels magnetischer kernresonanz.

Country Status (12)

Country Link
US (1) US4728575A (de)
EP (1) EP0160552B1 (de)
KR (1) KR920010391B1 (de)
AT (1) ATE61117T1 (de)
AU (1) AU585506B2 (de)
CA (1) CA1245553A (de)
DE (1) DE3581830D1 (de)
DK (1) DK168853B1 (de)
ES (1) ES8703019A1 (de)
HU (1) HU194741B (de)
IE (1) IE58354B1 (de)
IL (1) IL74985A (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US5017379A (en) * 1984-05-25 1991-05-21 Lemelson Jerome H Drug units and methods for treating blood clots
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
DE3508000A1 (de) * 1985-03-04 1986-09-04 Schering AG, Berlin und Bergkamen, 1000 Berlin Ferromagnetische partikel fuer die nmr-diagnostik
US5314642A (en) * 1984-11-27 1994-05-24 Igen, Inc. Interaction system comprising a surfactant-stabilized aqueous phase containing an antibody fragment
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US4951675A (en) * 1986-07-03 1990-08-28 Advanced Magnetics, Incorporated Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US5219554A (en) 1986-07-03 1993-06-15 Advanced Magnetics, Inc. Hydrated biodegradable superparamagnetic metal oxides
IL79559A0 (en) * 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US5320906A (en) * 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
AU610910B2 (en) * 1987-06-23 1991-05-30 Hafslund Nycomed Innovation Ab Improvements in and relating to magnetic resonance imaging
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
ATE99544T1 (de) * 1988-11-09 1994-01-15 Evan C Unger Liposomale radiologische kontrastmittel.
US5314681A (en) * 1988-12-23 1994-05-24 Nycomed Innovation Ab Composition of positive and negative contrast agents for electron spin resonance enhanced magnetic resonance imaging
JP3010500B2 (ja) * 1989-04-18 2000-02-21 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド 虚血性組織のリポゾームターゲッティング
US5230883A (en) * 1989-05-04 1993-07-27 Wisconsin Alumni Research Foundation Method for localization and treatment of tumors using polylysine complexes
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
US5064636A (en) * 1989-10-19 1991-11-12 Li King C P Paramagnetic oil emulsions as enteric MRI contrast agents
US5120527A (en) * 1989-10-19 1992-06-09 King Chuen Peter Li Paramagnetic oil emulsions as mri contrast agents
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5123414A (en) * 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5209720A (en) * 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5230882A (en) * 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5525232A (en) * 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
GB9024528D0 (en) * 1990-11-12 1991-01-02 Instrumentarium Corp Improvements in and relating to magnetic resonance imaging
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5240693A (en) * 1991-05-01 1993-08-31 University Of New Mexico Image enhancement by coadministration of biomodulators and structurally modified imaging agents
WO1992019264A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Biomodulators as universal imaging agents
WO1992021017A1 (en) * 1991-05-23 1992-11-26 Unger Evan C Liposoluble compounds for magnetic resonance imaging
US5443813A (en) * 1991-06-06 1995-08-22 Associated Universities, Inc. Loading and conjugating cavity biostructures
US5262532A (en) * 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5325860A (en) * 1991-11-08 1994-07-05 Mayo Foundation For Medical Education And Research Ultrasonic and interventional catheter and method
EP0804944A3 (de) 1992-05-04 1998-08-26 UNGER, Evan C Ein Verfahren zur Erzeugung einer Gaszusammensetzung in einem biologischen Gewebe oder Flüssigkeit in vivo
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5551429A (en) * 1993-02-12 1996-09-03 Fitzpatrick; J. Michael Method for relating the data of an image space to physical space
US5593688A (en) * 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5567410A (en) * 1994-06-24 1996-10-22 The General Hospital Corporation Composotions and methods for radiographic imaging
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6333971B2 (en) 1995-06-07 2001-12-25 George S. Allen Fiducial marker
US5833948A (en) * 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
ATE345682T1 (de) 1996-05-01 2006-12-15 Imarx Pharmaceutical Corp In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
DE69737915T2 (de) * 1996-09-11 2008-03-13 Bristol-Myers Squibb Medical Imaging, Inc. Verfahren zur diagnostischen Bilderzeugung der Nierenregion unter Verwendung eines Kontrastmittels und eines Vasodilators
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6537246B1 (en) 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
AU7104598A (en) 1997-04-09 1998-10-30 Philipp Lang New technique to monitor drug delivery noninvasively (in vivo)
US6060082A (en) * 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US7452551B1 (en) 2000-10-30 2008-11-18 Imarx Therapeutics, Inc. Targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6734171B1 (en) 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP2002511312A (ja) * 1998-04-09 2002-04-16 ナイコムド イメージング エーエス 生理学的パラメータを調べるための診断撮像における粒子状造影剤の使用
AU2001236798B2 (en) 2000-02-08 2004-11-04 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US20030133972A1 (en) * 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
US20030129223A1 (en) * 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
WO2002080981A2 (en) 2001-04-04 2002-10-17 Nordic Vaccine Technology A/S Polynucleotide binding complexes comprising sterols and saponins
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
WO2003079149A2 (en) * 2002-03-11 2003-09-25 The University Of Vermont And State Agriculture College Blood clotting predictor
US20090060992A1 (en) * 2002-05-08 2009-03-05 University Of Central Florida Research Foundation, Inc., Preparation of magneto-vesicles with DOPE/DDAB layers
WO2004023981A2 (en) * 2002-09-11 2004-03-25 Duke University Methods and compositions for blood pool identification, drug distribution quantification and drug release verification
US7769423B2 (en) * 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20060147509A1 (en) * 2002-10-02 2006-07-06 Kirkby Nikolai S Composition for vaccination
US20080241262A1 (en) * 2004-03-29 2008-10-02 The University Of Houston System Nanoshells and Discrete Polymer-Coated Nanoshells, Methods For Making and Using Same
WO2006031857A2 (en) * 2004-09-13 2006-03-23 Gilead Sciences, Inc. Delivering iron to an animal
WO2006051542A1 (en) * 2004-11-12 2006-05-18 Kpe Ltd. Nanoparticle mediated ultrasound therapy and diagnostic imaging
CA2680606C (en) 2006-03-29 2014-08-05 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
EP2010117A4 (de) * 2006-04-12 2010-12-01 Massachusetts Inst Technology Zusammensetzungen und verfahren zur adhäsionshemmung
WO2007127439A2 (en) 2006-04-28 2007-11-08 Children's Hospital Medical Center Compositions comprising fusogenic proteins or polypeptides derived from prosaposin for application in transmembrane drug delivery systems
US20080241065A1 (en) * 2007-03-27 2008-10-02 Benaron David A Systems and methods for the detection and analysis of in vivo circulating cells, entities, and nanobots
WO2008137114A1 (en) * 2007-05-04 2008-11-13 University Of Hawai'i Methods and compositions for targeted delivery of gene therapeutic vectors
DE102008005673A1 (de) * 2008-01-23 2009-08-20 Universität Augsburg Bläschen, sowie Verfahren zur Herstellung und Manipulation von Bläschen
EP3115060A1 (de) 2008-04-18 2017-01-11 VaxInnate Corporation Flagellin deletionsmutanten und deren verwendung
WO2009142744A2 (en) * 2008-05-20 2009-11-26 The University Of Vermont And State Agriculture College Predicting hemostatic risk; dependence on plasma composition
US8797031B2 (en) * 2011-01-27 2014-08-05 Siemens Medical Solutions Usa, Inc. MR imaging system for discriminating between imaged tissue types
EP2741784B1 (de) 2011-03-02 2017-05-17 Board Of Regents, The University Of Texas System Tusc2 therapien
CN103565745A (zh) 2012-08-10 2014-02-12 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
US10736880B2 (en) 2015-12-18 2020-08-11 The Board Of Regents Of The University Of Texas Systems Therapeutics for preterm labor management
MA46542A (fr) 2016-10-12 2021-03-31 Univ Texas Procédés et compositions pour une immunothérapie par tusc2
CN111511484A (zh) 2017-11-04 2020-08-07 索纳纳米技术公司 金属纳米颗粒及制备所述金属纳米颗粒的方法
MX2020009829A (es) 2018-03-23 2021-01-08 Bexion Pharmaceuticals Inc Composiciones farmaceuticas de saposina c y metodos para tratar el cancer.
US20210395721A1 (en) 2018-10-24 2021-12-23 Codiak Biosciences, Inc. Methods to improve potency of electroporation
US20220136011A1 (en) 2019-02-08 2022-05-05 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
AU2021260578A1 (en) 2020-04-20 2022-11-03 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
US20230302154A1 (en) 2020-08-19 2023-09-28 The Board Of Regents Of The University Of Texas System Nanodrugs for targeted drug delivery and use thereof
WO2023225160A1 (en) 2022-05-18 2023-11-23 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3850578A (en) * 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US4320121A (en) * 1976-10-12 1982-03-16 Sears Barry D Method of emulsifying cholesterol, cholesterol esters and triglyceride compounds
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
DE3000483A1 (de) * 1979-01-09 1980-07-17 Fuji Photo Film Co Ltd Mikrokapseln fuer immunologische bestimmungen
US4301054A (en) * 1979-06-04 1981-11-17 Thermal Imagery, Inc. Thermographic cholesteric coating compositions
GR77320B (de) * 1980-12-22 1984-09-11 Procter & Gamble
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4442834A (en) * 1981-10-02 1984-04-17 Jobst Institute, Inc. Pneumatic splint
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
CA1243602A (en) * 1983-08-25 1988-10-25 Hong-Ning Yeung Methods for enhancing the contrast in nmr imaging

Also Published As

Publication number Publication date
ES542604A0 (es) 1987-01-16
IE851035L (en) 1985-10-27
DK188785A (da) 1985-10-28
ES8703019A1 (es) 1987-01-16
HUT37569A (en) 1986-01-23
DK188785D0 (da) 1985-04-26
KR920010391B1 (ko) 1992-11-27
AU585506B2 (en) 1989-06-22
DK168853B1 (da) 1994-06-27
EP0160552B1 (de) 1991-02-27
IL74985A (en) 1989-03-31
EP0160552A3 (en) 1986-08-20
CA1245553A (en) 1988-11-29
IE58354B1 (en) 1993-09-08
HU194741B (en) 1988-03-28
AU4170385A (en) 1985-10-31
IL74985A0 (en) 1985-08-30
US4728575A (en) 1988-03-01
EP0160552A2 (de) 1985-11-06
KR850007562A (ko) 1985-12-07
ATE61117T1 (de) 1991-03-15

Similar Documents

Publication Publication Date Title
DE3581830D1 (de) Kontrastmittel zur bilderzeugung mittels magnetischer kernresonanz.
IL79333A (en) Method and kit for imaging lymphatic structures
EP0314262A3 (en) Mri system with open access to patient image volume
DE3482336D1 (de) Geraet zur bilderzeugung mittels magnetischer kernresonanz.
MX205459A (es) Agentes de contraste para resonancia magnetica nuclear y proceso para su preparacion
GB8501442D0 (en) Electromagnet
GB2177199A (en) Magnetic micro-particles as contrast agents in nuclear magnetic resonance imaging
SE8800767D0 (sv) Nmr-apparat for undersokning av en kropp, serskilt for avbildning av menniskokroppens hud, och anordning for alstring av en magnetfeltsgradient i en sadan apparat
DK0470188T3 (da) Hidtil ukendte magnetiske resonans-imaging-midler
JPS6490439A (en) Silver halide photographic sensitive material
Fam Biological effects of 60-Hz magnetic field on mice
Zatsepin et al. Theory of a superposed linear transducer
Le Grimellec et al. Effect of meleate on membrane physical state of brush border and basolateral membranes of the dog kidney
Kusama et al. Hyaline cells in minor salivary gland tumors Morphological, immunohistochemical and electron microscopic study
JPS55118051A (en) Method and apparatus for developing
Laron et al. Immunological investigations of sheep prolactin
FR2613076B1 (fr) Procede d'imagerie rapide par resonance magnetique nucleaire
Jones IMS advances in understanding Terrestrial myriametric radiation
Liburdy et al. The influence of oscillating electromagnetic fields on membrane structure and function: Synthetic liposome and natural membrane bilayer systems with direct application to the controlled delivery of chemical agents
Zhang The role of free apolipoprotein AI in reverse cholesterol transport: Characterization of high-density lipoprotein particles formed in cholesterol efflux
Kozharinov et al. Experimental investigation of model defects in high-strength electro-magnetic fields.
De Cuyper et al. Free-Flow Electrophoresis as a Suitable Tool to Explore Intervesicular Interactions
GOLINSKAYA et al. Unit for exposure of biological objects to static magnetic field
Brookes The proton leak and fatty acid composition of mitochondrial inner membrane phospholipid liposomes
Charlemagne et al. Hypertrophied rat heart. New Na+ K+ ATPase-ouabain interactions in sarcolemma vesicles?: I/Isolation of sarcolemma and ouabain-binding

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEXSTAR PHARMACEUTICALS, INC. (N.D.GES.D.STAATES D